BusinessAXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS PatientsBy Nasdaq OMXJan 23, 2018, 2:02 PM UTC
BusinessAXIM Biotech Advisory Board Member Presented at CannMed 2017 Personalized Cannabinoid Medicine Conference at HarvardBy Nasdaq OMXApr 13, 2017, 1:01 PM UTC
BusinessAXIM Biotech Advisory Board Member Presented at CannMed 2017 Personalized Cannabinoid Medicine Conference at HarvardBy Nasdaq OMXApr 13, 2017, 1:01 PM UTC
BusinessNew U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum ProductsBy Nasdaq OMXNov 16, 2016, 2:01 PM UTC
BusinessNew U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum ProductsBy Nasdaq OMXNov 16, 2016, 2:01 PM UTC
BusinessAXIM® Biotechnologies, Inc. Publishes Product Pipeline Chart for Pharmaceutical Clinical Trials Program in Cannabinoid R&DBy Nasdaq OMXNov 3, 2016, 1:01 PM UTC
BusinessAXIM® Biotechnologies, Inc. Publishes Product Pipeline Chart for Pharmaceutical Clinical Trials Program in Cannabinoid R&DBy Nasdaq OMXNov 3, 2016, 1:01 PM UTC
BusinessAXIM® Biotechnologies, Inc. Secures Funding to Continue Pharmaceutical Clinical Trials Program in Cannabinoid Research and Development for Multiple IndicationsBy Nasdaq OMXOct 26, 2016, 1:04 PM UTC
